Comparative Pharmacology
Head-to-head clinical analysis: AKRINOL versus RETIN A MICRO.
Peer-Reviewed Evidence
Head-to-head clinical analysis: AKRINOL versus RETIN A MICRO.
AKRINOL vs RETIN-A-MICRO
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Not available; likely a combination product with antihistaminic and sympathomimetic actions.
Retinoid agonist that binds to and activates retinoic acid receptors (RARs), modulating gene expression involved in cell proliferation, differentiation, and keratinization, leading to normalization of follicular keratinization and reduced comedone formation.
Adults: 100 mg orally twice daily.
Topical, apply a pea-sized amount to the entire face once daily at bedtime.
None Documented
None Documented
3-4 hours (prolonged to 8-12 hours in renal impairment; no dose adjustment typically needed unless CrCl <30 mL/min).
Terminal elimination half-life is approximately 0.5-2 hours after topical application, though prolonged due to slow release from microsphere formulation. Clinical context: rapid clearance limits systemic accumulation.
Primarily renal (80-90% as unchanged drug via glomerular filtration and tubular secretion); minor biliary/fecal (5-10%).
Tretinoin is metabolized in the liver via CYP450 enzymes, primarily CYP2A6 and CYP3A4. Metabolites are eliminated via bile and feces (approximately 60%) and urine (approximately 30%), with less than 1% of unchanged drug excreted renally.
Category C
Category C
Topical Retinoid
Topical Retinoid